What is the recommended fluconazole (Diflucan) dosing for an adult with a vaginal yeast infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 5, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Fluconazole Dosing for Vaginal Yeast Infection

For uncomplicated vaginal yeast infection in adults, administer fluconazole (Diflucan) 150 mg as a single oral dose. 1

Standard Treatment Regimen

  • The FDA-approved dose is fluconazole 150 mg taken orally once for uncomplicated vulvovaginal candidiasis 1
  • This single-dose regimen achieves therapeutic concentrations in vaginal secretions rapidly and maintains them long enough to produce high clinical and mycological cure rates 2
  • Clinical cure rates range from 92-99% at short-term evaluation (5 days post-treatment), with 88-91% efficacy maintained at long-term follow-up (27-100 days) 2, 3

Alternative Topical Options

If oral therapy is not preferred or contraindicated, topical azole antifungals are equally effective alternatives 4:

  • Over-the-counter options include clotrimazole cream (1% for 7-14 days or 2% for 3 days), miconazole cream or suppositories (various formulations from single-dose to 7-day regimens), or tioconazole 6.5% ointment as a single application 4
  • Prescription topical agents include butoconazole 2% cream (single dose), terconazole cream (0.4% for 7 days or 0.8% for 3 days), or terconazole 80 mg suppositories (one daily for 3 days) 4

Complicated or Recurrent Vulvovaginal Candidiasis

For patients with complicated VVC (severe symptoms, non-albicans species, immunocompromised status, uncontrolled diabetes, or pregnancy) or recurrent episodes (≥4 episodes per year):

  • Initial treatment requires longer duration therapy rather than single-dose fluconazole 4
  • For recurrent VVC after initial control, maintenance suppression with fluconazole 150 mg weekly for 6 months is recommended 4
  • Chronic suppressive therapy with fluconazole 100 mg three times weekly can be used for patients with frequent recurrences 4

Important Clinical Considerations

When Single-Dose Therapy May Be Insufficient

  • Severe vulvovaginal symptoms (extensive vulvar erythema, edema, excoriation, or fissure formation) may require extended therapy 4
  • Non-albicans Candida species (particularly C. glabrata) may be less susceptible to fluconazole and require alternative agents or longer treatment courses 4
  • Immunocompromised patients (including those with poorly controlled diabetes or HIV) often need extended treatment regimens 4

Common Pitfalls to Avoid

  • Do not use fluconazole in the first trimester of pregnancy due to potential teratogenic effects at therapeutic doses; topical azoles are preferred throughout pregnancy 4
  • The most common adverse effects are mild gastrointestinal symptoms (nausea 7%, abdominal pain 6%, diarrhea 3%) and headache (13%), which are generally self-limited 1
  • Treatment failure or early recurrence should prompt consideration of non-albicans species, reinfection from sexual partner, or underlying predisposing factors (diabetes, immunosuppression, antibiotic use) 4

Efficacy Compared to Topical Therapy

  • Single-dose oral fluconazole 150 mg demonstrates equivalent or superior efficacy compared to multi-day intravaginal clotrimazole regimens, with better patient compliance and satisfaction 5
  • At one-month follow-up, oral fluconazole shows significantly lower recurrence rates compared to intravaginal clotrimazole (1.4% vs 24.3%) 5

References

Research

Treatment of vaginal candidiasis with a single oral dose of fluconazole. Multicentre Study Group.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 1988

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.